Create Free Account

By creating account you will get access to hot stocks & personalised emails

Actinogen Medical Ltd

Healthcare AU ACW

0.032AUD
-0.008(20.00%)

Last update at 2025-03-04T05:10:00Z

Day Range

0.030.04
LowHigh

52 Week Range

0.020.10
LowHigh

Fundamentals

  • Previous Close 0.04
  • Market Cap125.31M
  • Volume24739532
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.92117M
  • Revenue TTM9.93M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM 9.93M
  • Diluted EPS TTM-0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -10.75227M -9.49737M -3.91507M -5.33053M -9.88768M
Minority interest - - - - -
Net income -10.75227M -9.51585M -5.92146M -8.87581M -10.36458M
Selling general administrative 6.57M 4.56M 3.11M 2.21M 0.79M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.08M
Reconciled depreciation 0.41M 0.40M 0.39M 0.41M 0.35M
Ebit -10.73567M -9.47889M -3.89275M -5.30165M -9.40279M
Ebitda -10.33006M -9.07822M -3.50605M -4.88871M -9.04930M
Depreciation and amortization 0.41M 0.40M 0.39M 0.41M 0.35M
Non operating income net other - - - - -
Operating income -10.73567M -9.47889M -3.89275M -5.30165M -9.40279M
Other operating expenses 15.87M 13.17M 5.90M 8.91M 14.47M
Interest expense 0.02M 0.02M 0.02M 0.03M 0.00799M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.37M 0.04M 0.03M 0.03M 0.00799M
Net interest income 0.35M 0.02M 0.00477M -0.02888M 0.20M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.79M 0.02M 2.01M 3.55M 0.48M
Total revenue 0.37M 0.04M 0.03M 0.09M 0.08M
Total operating expenses 15.87M 13.17M 5.90M 8.91M 14.47M
Cost of revenue - - - - -
Total other income expense net 4.77M -0.01848M -0.02232M -0.02888M -0.48489M
Discontinued operations - - - - -
Net income from continuing ops -10.75227M -9.49737M -3.91507M -5.33053M -9.88768M
Net income applicable to common shares -10.75227M -9.49737M -3.91507M -5.33053M -9.88768M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 21.31M 15.21M 23.31M 18.38M 11.94M
Intangible assets - 2.41M 2.72M 3.03M 3.35M
Earning assets - - - - -
Other current assets 0.11M - - - 0.46M
Total liab 1.62M 1.80M 1.57M 0.92M 1.05M
Total stockholder equity 19.70M 13.41M 21.74M 17.46M 10.89M
Deferred long term liab - - - - -
Other current liab 0.70M 0.70M 0.58M 0.36M 0.70M
Common stock 100.02M 78.71M 76.94M 60.05M 47.92M
Capital stock - 78.71M 76.94M 60.05M 47.92M
Retained earnings -81.73583M -68.69155M -57.93928M -48.44191M -44.52685M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M - - 0.04M 0.04M
Cash 9.45M 8.46M 16.37M 13.42M 5.04M
Cash and equivalents - 7.18M 12.10M 7.10M 3.56M
Total current liabilities 1.36M 1.80M 1.48M 0.76M 0.74M
Current deferred revenue - -0.08693M -0.07834M -0.07117M -0.08602M
Net debt -9.13167M -8.37314M -16.20501M -13.18521M -4.65062M
Short term debt 0.06M 0.09M 0.08M 0.07M 0.09M
Short long term debt - - - - -
Short long term debt total 0.32M 0.09M 0.17M 0.24M 0.39M
Other stockholder equity -10.48337M -14.96128M -23.94410M -15.72197M -6.79131M
Property plant equipment - 0.11M 0.17M 0.25M 0.39M
Total current assets 18.88M 12.69M 20.42M 15.06M 8.16M
Long term investments - - - - -
Net tangible assets - 11.00M 19.02M 14.42M 7.54M
Short term investments - - - - -
Net receivables 9.32M 4.23M 4.05M 1.63M 2.66M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.60M 1.10M 0.90M 0.39M 0.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 11.89M 3.39M 2.74M 5.85M 7.49M
Additional paid in capital - - - - -
Common stock total equity - - - - 47.92M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.09M -2.52042M -2.88943M -3.28716M -3.73699M
Deferred long term asset charges - - - - -
Non current assets total 2.44M 2.52M 2.89M 3.32M 3.77M
Capital lease obligations - 0.09M 0.17M 0.24M 0.39M
Long term debt total - 0.00000M 0.09M 0.17M 0.30M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.03660M -0.00294M -0.00619M -0.02276M 0.07M
Change to liabilities 0.25M 0.69M 0.11M 0.08M -0.21565M
Total cashflows from investing activities -0.03660M -0.00294M -0.00619M -0.02276M 0.07M
Net borrowings -0.07834M -0.07117M -0.08410M -0.07774M -0.07774M
Total cash from financing activities 0.82M 12.42M 10.11M 0.28M 8.17M
Change to operating activities 0.06M 0.03M -0.08422M 0.02M 0.00479M
Net income -10.75227M -9.49737M -3.91507M -5.33053M -10.36458M
Change in cash -7.91021M 2.95M 8.38M -2.59612M -2.26016M
Begin period cash flow 16.37M 13.42M 5.04M 7.64M 9.90M
End period cash flow 8.46M 16.37M 13.42M 5.04M 7.64M
Total cash from operating activities -8.69824M -9.51713M -1.72390M -2.85561M -10.49830M
Issuance of capital stock 0.90M 13.32M 10.91M - 7.92M
Depreciation 0.41M 0.40M 0.39M 0.41M 0.35M
Other cashflows from investing activities - - - 0.00000M 0.07M
Dividends paid - - 0.36M 10.20M -
Change to inventory - - - - -
Change to account receivables -0.18167M -2.41232M 1.49M 1.77M -1.35811M
Sale purchase of stock -0.83129M -0.83129M -0.71587M -0.71587M 7.92M
Other cashflows from financing activities 0.75M -0.07117M 0.64M 0.64M 0.80M
Change to netincome 1.52M 1.27M 0.29M 0.19M 0.60M
Capital expenditures 0.04M 0.00294M 0.00619M 0.02M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.18167M -2.41232M 1.49M 1.77M -9.18965M
Stock based compensation 1.52M 1.29M 0.29M 0.19M -
Other non cash items 1.65M -0.42043M 1.80M 2.06M 9.53M
Free cash flow -8.73484M -9.52007M -1.73009M -2.87837M -0.02276M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACW
Actinogen Medical Ltd		 -0.008 20.00% 0.03 - 25.97 12.62 4.97 - -9.9502
CSL
CSL Ltd		 2.71 1.03% 264.71 30.24 40.82 8.28 4.38 6.24 19.37
TLX
Telix Pharmaceuticals Ltd		 -1.09 3.76% 27.87 188.27 66.67 12.07 17.90 12.82 108.49
MSB
Mesoblast Ltd		 -0.21 8.37% 2.30 - 454.55 540.27 4.14 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.88 6.66% 12.33 14.31 35.21 9.53 4.90 6.12 7.98

Reports Covered

Stock Research & News

View All

Profile

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Actinogen Medical Ltd

109 Pitt Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. MD, CEO & Director 1960
Mr. Jeff Carter BFinAdmin, MAppFin Chief Financial Officer 1958
Ms. Tamara Miller Sr. VP of Product Devel. NA
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. Chief Medical Officer NA
Mr. Michael Roberts Head of Investor Relations & Corp. Communications NA
Ms. Therese Russell Head of People & Infrastructure NA
Dr. Christian Toouli Head of Bus. Devel. NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec. 1963
Dr. Dana C. Hilt M.D. Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board 1953
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. Head of Clinical Pharmacology & Lead Physician and Depression NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

Market Research
ISO Certified pcidss

Kalkine Solutions Private Limited, an authorized representative of Kalkine Pty Ltd, holds the ISO 27001:2022 certification (Certificate No. IC-IS-2404072) and the PCI-DSS Version 4.0 Level 1 certification (Certificate No. CSNL1PCI8067).

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2025 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.